After Today’s Bearish Options Activity, Is Boston Scientific Corporation’s Near-Term Analysis Positive?

 After Today's Bearish Options Activity, Is Boston Scientific Corporation's Near Term Analysis Positive?

In today’s session Boston Scientific Corporation (BSX) recorded an unusually high (436) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious BSX decrease. With 436 contracts traded and 16564 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: BSX161118P00023000 closed last at: $0.67 or 19.6% up. About 1.44 million shares traded hands. Boston Scientific Corporation (NYSE:BSX) has risen 34.02% since March 2, 2016 and is uptrending. It has outperformed by 25.77% the S&P500.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on October, 26. They expect $0.27 earnings per share, up 12.50% or $0.03 from last year’s $0.24 per share. BSX’s profit will be $363.89M for 21.65 P/E if the $0.27 EPS becomes a reality. After $0.27 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Boston Scientific Corporation (NYSE:BSX) Ratings Coverage

Out of 22 analysts covering Boston Scientific Corporation (NYSE:BSX), 17 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 77% are positive. $28 is the highest target while $19 is the lowest. The $23.96 average target is 2.48% above today’s ($23.38) stock price. Boston Scientific Corporation has been the topic of 28 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, April 28 by Wedbush. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Outperform” rating by RBC Capital Markets on Thursday, April 28. Argus Research upgraded the shares of BSX in a report on Thursday, September 1 to “Buy” rating. The rating was upgraded by Goldman Sachs on Thursday, August 27 to “Neutral”. The stock of Boston Scientific Corporation (NYSE:BSX) has “Corporate” rating given on Thursday, October 29 by FinnCap. Suntrust Robinson initiated the shares of BSX in a report on Thursday, February 25 with “Buy” rating. As per Thursday, March 17, the company rating was initiated by Nomura. The firm has “Overweight” rating by JP Morgan given on Friday, July 29. The firm has “Buy” rating by Guggenheim given on Thursday, June 9. The firm has “Buy” rating by Needham given on Friday, July 29.

According to Zacks Investment Research, “Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of minimally invasive medical devices. The company’s products are used in a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, radiology, urology and vascular surgery.”

Insitutional Activity: The institutional sentiment increased to 1.16 in 2016 Q2. Its up 0.23, from 0.93 in 2016Q1. The ratio improved, as 25 funds sold all Boston Scientific Corporation shares owned while 168 reduced positions. 63 funds bought stakes while 160 increased positions. They now own 1.23 billion shares or 2.15% less from 1.26 billion shares in 2016Q1.
Moreover, Hbk Invests Limited Partnership has 0.02% invested in Boston Scientific Corporation (NYSE:BSX) for 104,719 shares. Allianz Asset Ag last reported 890,327 shares in the company. Gateway Invest Advisers Ltd Co has 0.28% invested in the company for 1.38 million shares. Glenmede Tru Commerce Na reported 45,720 shares or 0.01% of all its holdings. Sector Gamma As last reported 1.41M shares in the company. Mizuho Tru & Banking Limited accumulated 0.15% or 2.16 million shares. General Electric Co last reported 0.87% of its portfolio in the stock. Wellington Group Limited Liability Partnership has 0.55% invested in the company for 90.79 million shares. Boston Family Office Ltd Co last reported 30,875 shares in the company. Rainier Inv Mgmt Llc accumulated 1.07% or 949,120 shares. Artemis Investment Management Ltd Liability Partnership accumulated 0.43% or 1.12 million shares. Dekabank Deutsche Girozentrale last reported 0.1% of its portfolio in the stock. Carroll Assoc Inc accumulated 2,500 shares or 0.01% of the stock. First Retail Bank Of Omaha reported 223,979 shares or 0.39% of all its holdings. Evercore Wealth Lc, a New York-based fund reported 10,564 shares.

Insider Transactions: Since April 27, 2016, the stock had 0 buys, and 16 sales for $15.01 million net activity. $62,020 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Sorenson John Bradley on Wednesday, May 11. The insider Mahoney Michael F sold $2.21 million. $1.74 million worth of Boston Scientific Corporation (NYSE:BSX) was sold by Fitzgerald Joseph Michael on Tuesday, May 3. Shares for $541,038 were sold by Mirviss Jeffrey B.. Another trade for 24,000 shares valued at $526,438 was made by Pratt Timothy A. on Monday, May 2. 78,122 shares were sold by Ballinger Kevin J., worth $1.88M. On Wednesday, July 20 Phalen Michael P. sold $841,050 worth of the stock or 35,000 shares.

Boston Scientific Corporation is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The company has a market cap of $31.51 billion. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions , Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It currently has negative earnings. It operates in three divisions: Cardiovascular, Rhythm Management and MedSurg.

BSX Company Profile

Boston Scientific Corporation, incorporated on June 22, 1979, is a developer, maker and marketer of medical devices that are used in a range of interventional medical specialties. The Firm offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. The Firm operates through three divisions: Cardiovascular, Rhythm Management and MedSurg. The Company’s Cardiovascular segment consists of Interventional Cardiology and PI businesses. The Company’s Rhythm Management segment consists of CRM and EP businesses. The Company’s MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses.

Another recent and important Boston Scientific Corporation (NYSE:BSX) news was published by Prnewswire.com which published an article titled: “Boston Scientific Receives CE Mark For LOTUS Edgeâ„¢ Valve System” on September 19, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment